Cytomed TherapeuticsGDTC
13F holders, Q1 2024 (March 31)1holders
$2.15avg. 13F price*
At the end of Q1 2024, 1 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings. The largest holder was Tower Research Capital LLC (TRC) ($28).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $17K |
Ownership 1 holders
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -98.5% | 13 | $28 |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.